Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Conditions

• Locally Advanced or Metastatic Renal Cell Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Cabozantinib monotherapy — DRUG
  Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
• All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC — DRUG
  As per authorized FDA label in advanced RCC

Study Details

To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyrosine Kinase Inhibitor (TKI) (a type of targeted cancer drug) immediately after Check Point Inhibitor (CPI) treatment (a type of immunotherapy that blocks proteins that stop the immune system from attacking the cancer cells) in US community oncology practices will be analyzed.

Key Dates

Start date

Jan 30, 2020

Status verified

Nov 2021

Primary completion

Jun 5, 2020

Completion

Jun 5, 2020

Study Design

Enrollment

247 participants (actual)

Arms

• Arm: cabozantinib arm
• Arm: non cabozantinib Tyrosine Kinase Inhibitors (TKI) arm

Primary Outcome Measure

6 months Real-World Response Rate [ Time Frame: From start of index treatment until 6 months of follow up or end of the treatment or death whichever occurs first ]

Locations (1)

Find similar trials in The Woodlands, TX